The U.S. Supreme Court has been petitioned to reinstate mail-order access to mifepristone, a widely used abortion pill. The request follows a Friday ruling by the Fifth Circuit Court of Appeals that temporarily reimposed a requirement for the medication to be dispensed in person.
Danco Laboratories, a maker of mifepristone, filed an emergency application on Saturday, arguing that the appellate court's decision "causes immediate confusion and dramatic upheaval." The filing contends that the ruling creates "chaos for patients, providers, pharmacies, and the drug-regulatory system," constituting an "irreparable harm" that necessitates urgent intervention.
The Fifth Circuit's order partially overrides a prior ruling that had paused the case pending an FDA review. This development curtails access to the pill, the most common method for terminating pregnancies in the U.S., particularly in states where abortion is already banned. Two drug manufacturers, Danco Laboratories and GenBioPro, have submitted applications to the top court, seeking to pause the appellate ruling while legal challenges continue.
Read More: Comey charged for Instagram post; DOJ to review threats case by case
Broader Implications and Past Rulings
The appeals court's decision represents a significant shift in abortion policy, especially since the Supreme Court's 2022 decision to overturn Roe v. Wade. The current challenge to mifepristone's availability comes two years after the justices unanimously rejected a similar legal challenge, finding that the plaintiffs lacked standing. The application was filed with Justice Samuel Alito, who will likely refer it to the full court.
Opponents of abortion, such as Anthony Pro-Life America, have applauded the appellate ruling. States like Louisiana, led by Republican lawmakers, have prioritized restricting access to mifepristone, including through telehealth services from out-of-state providers. The ruling, affecting nationwide distribution, is seen as a major victory for anti-abortion activists.
